利培酮治疗12例发育障碍和注意力缺陷/多动障碍儿童。
Risperidone treatment in 12 children with developmental disorders and attention-deficit/hyperactivity disorder.
作者信息
Eapen Valsamma, Gururaj A K
机构信息
Department of Psychiatry, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
出版信息
Prim Care Companion J Clin Psychiatry. 2005;7(5):221-4. doi: 10.4088/pcc.v07n0502.
BACKGROUND
Risperidone is a novel antipsychotic drug that has been tried in the treatment of several child psychiatric disorders. In an open clinical study, we evaluated the safety and efficacy of risperidone in children with developmental disorder and behavioral problems including attention-deficit/hyperactivity disorder (ADHD).
METHOD
Twelve patients aged 4 to 14 years who had a DSM-IV-diagnosed developmental disorder and ADHD in addition to other behavioral problems, in particular aggression, were treated with risperidone for a period of up to 2 years with daily doses ranging from 1 to 3 mg. Data were gathered from December 2002 to December 2004.
RESULTS
A positive clinical response was noted in 9 of the 12 patients within 3 months of study recruitment according to the Clinical Global Impressions-Improvement scale. Risperidone was well tolerated by all 12 patients. The most commonly reported side effect was sedation, which necessitated dosage reduction in 2 patients, but not discontinuation.
CONCLUSIONS
Our findings suggest that risperidone may be an effective and safe treatment for children and adolescents with developmental disorder and disruptive behaviors.
背景
利培酮是一种新型抗精神病药物，已用于治疗多种儿童精神疾病。在一项开放性临床研究中，我们评估了利培酮治疗患有发育障碍和行为问题（包括注意力缺陷多动障碍（ADHD））儿童的安全性和有效性。
方法
12名年龄在4至14岁之间、除其他行为问题（尤其是攻击性）外还患有DSM-IV诊断的发育障碍和ADHD的患者，接受了为期2年的利培酮治疗，每日剂量为1至3毫克。数据收集时间为2002年12月至2004年12月。
结果
根据临床总体印象改善量表，12名患者中有9名在研究招募后的3个月内出现了积极的临床反应。12名患者对利培酮耐受性良好。最常报告的副作用是镇静，2名患者因此需要减少剂量，但未停药。
结论
我们的研究结果表明，利培酮可能是治疗患有发育障碍和破坏性行为的儿童及青少年的一种有效且安全的治疗方法。
Zotero 插件